Treatment of Multiple Myeloma with VLA4-targeted Nanoparticles Delivering Novel c-MYC Inhibitor Prodrug
Abstract
Rationale: Multiple myeloma (MM) is an incurable malignancy derived from antibody secreting B lineage plasma cells. MM is the second most common malignancy in the United States and accounts for 1% of cancer deaths. Despite recent advances, the 5-year survival rate in patients with MM is less than 40% MM responds well to chemotherapy and remissions occur in that majority of MM patients, but all patients eventually relapse and die from progressive disease within 6 years. If the residual post-remission cells of their activation to progressive disease could be disrupted with novel targeted therapies. It would have a significant impact on the care and treatment of MM patients, particularly male veterans who are at 51% increased risk of MM compared to general public.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2012
- Accession Number
- ADA585947
Entities
People
- Michael Tomasson
Organizations
- Washington University in St. Louis